Terumo Blood and Cell Technologies (Terumo BCT), recently held a localisation launch ceremony themed 'Unlocking a New Chapter in China, Led by Purpose, Built on Quality' in Hangzhou, Zhejiang Province.

The company announced a strategic partnership with Terumo Medical Products (Hangzhou) Co. (TMPH), establishing an entrust manufacturing arrangement the TMPH facility located in Qiantang District, Hangzhou, marking a solid step forward for its localization journey. With this strategic move, Terumo BCT aims to debut its local manufacturing capabilities in the Chinese market, providing high-quality locally made products to Chinese customers to better serve Chinese patients, injecting new dynamics into China’s 'New Quality Productive Forces' initiative and facilitating the ambitions of the "Healthy China 2030" agenda.

The localisation launch ceremony also signifies the successful completion of the first phase of Terumo BCT's localization strategy. For the company, the key target of this phase is to work with Terumo Medical Products (Hangzhou) Co., Ltd, also a subsidiary of the Terumo Corporation, to fully utilise its expertise and manufacturing capabilities to co-build a stable, reliable, efficient and flexible local supply chain to ensure the delivery of high-quality 'made-in-China' medical products to the Chinese market.

The commencement of production of Terumo BCT products will establish TMPH as a uniquely positioned manufacturing site within the Group, producing products from all three Terumo Companies: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company (Terumo BCT).

For Terumo BCT, the first products to be locally manufactured in China include:

• Trima Accel^™ Automated Blood Collection System and disposable sets
• Spectra Optia™ Apheresis System and disposable sets

By signing agreements on manufacturing and quality, Terumo BCT and TMPH have established a unified quality management system. The system will strictly control every detail in production processes, adopt science-based workflows and both international and Chinese standards, and ensure that locally manufactured products maintain the same quality in technology and quality as those in the Japanese, European and American markets.